Katja Stefan

Katja Stefan

Auto-generated profile, based on publicly available information

Katja Stefan

Lübeck Institute of Experimental Dermatology (LIED), Medicinal Chemistry and Systems Polypharmacology, University of Lübeck and University Medical Center Schleswig-Holstein (UKSH), Ratzeburger Allee 160, 23538 Lübeck, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SPSachin Puri
Sachin Puri
KSKatja Stefan
Katja Stefan
SKSharuk Khan
Sharuk Khan
Jens PahnkeJens Pahnke
Jens Pahnke
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
KJKapil Juvale
Kapil Juvale

9 December 2021 in Bioinformatics
Verified
Journal Article
Open access
PDF file
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
KSKatja Stefan
Katja Stefan
KSKatja Silbermann
Katja Silbermann
Jens PahnkeJens Pahnke
Jens Pahnke
MWMichael Wiese
Michael Wiese
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
Multitargeting features of small molecules have been of increasing interest in recent years. Polypharmacological drugs that address several therapeutic targets may provide greater therapeutic benefits for patients. Furthermore, multitarget compounds can be used to address proteins of the same (or similar) protein families for their exploration as potential pharmacological targets. In addition, the knowledge of multitargeting features is of major importance in the drug selection process; particularly in ultra-large virtual screening procedures to gain high-quality compound collections. However, large-scale multitarget modulator landscapes are almost non-existent. We implemented a specific feature-driven computer-aided pattern analysis (C@PA) to extract molecular-structural features of inhibitors of the model protein family of ATP-binding cassette (ABC) transporters. New molecular-structural features have been identified that successfully expanded the known multitarget modulator landscape of pan-ABC transporter inhibitors. The prediction capability was biologically confirmed by the successful discovery of pan-ABC transporter inhibitors with a distinct inhibitory activity profile. The multitarget dataset is available on the PANABC web page (http://www.panabc.info) and its use is free of charge. Supplementary data are available at Bioinformatics online.

26 October 2020 in Future Drug Discovery
Verified
Journal Article
Open access
KSKatja Stefan
Katja Stefan
LLLionel Yi Wen Leck
Lionel Yi Wen Leck
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
PBPablo Bascuñana
Pablo Bascuñana
MHMichael Li-Hsuan Huang
Michael Li-Hsuan Huang
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan

23 May 2024 in Scientific Data
Verified
Journal Article
Open access
PDF file
KSKatja Stefan
Katja Stefan
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
The identification of lead molecules and the exploration of novel pharmacological drug targets are major challenges of medical life sciences today. Genome‐wide association studies, multi-omics, and systems pharmacology steadily reveal new protein networks, extending the known and relevant disease-modifying proteome. Unfortunately, the vast majority of the disease-modifying proteome consists of ‘orphan targets’ of which intrinsic ligands/substrates, (patho)physiological roles, and/or modulators are unknown. Undruggability is a major challenge in drug development today, and medicinal chemistry efforts cannot keep up with hit identification and hit-to-lead optimization studies. New ‘thinking-outside-the-box’ approaches are necessary to identify structurally novel and functionally distinctive ligands for orphan targets. Here we present a unique dataset that includes critical information on the orphan target ABCA1, from which a novel cheminformatic workflow – computer-aided pattern scoring (C@PS) – for the identification of novel ligands was developed. Providing a hit rate of 95.5% and molecules with high potency and molecular-structural diversity, this dataset represents a suitable template for general deorphanization studies.

19 June 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
Jörg HaupenthalJörg Haupenthal
Jörg Haupenthal
Muhammad RafehiMuhammad Rafehi
Muhammad Rafehi
AKAndreas Martin Kany
Andreas Martin Kany
ALAnne Lespine
Anne Lespine
KSKatja Stefan
Katja Stefan
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
Energy‐coupling factor transporters (ECFTs) are membrane‐bound ATP‐binding cassette (ABC) transporters in prokaryotes that are found in pathogens against which novel antibiotics are urgently needed. To date, just 54 inhibitors of three molecular‐structural classes with mostly weak inhibitory activity are known. Target repurposing is a strategy that transfers knowledge gained from a well‐studied protein family to under‐studied targets of phylogenetic relation. Forty‐eight human ABC transporters are known that may harbor structural motifs similar to ECFTs to which particularly multitarget compounds may bind. We assessed 31 multitarget compounds which together target the entire druggable human ABC transporter proteome against ECFTs, of which nine showed inhibitory activity (hit rate 29.0%) and four demonstrated moderate to strong inhibition of an ECFT (IC50 values between 4.28 and 50.2 µM) as well as antibacterial activity against ECFT‐expressing Streptococcus pneumoniae. Here, ivermectin was the most potent candidate (MIC95: 22.8 µM), and analysis of five ivermectin derivatives revealed moxidectin as one of the most potent ECFT‐targeting antibacterial agents (IC50: 2.23 µM; MIC95: 2.91 µM). Distinct molecular‐structural features of avermectins and derivatives as well as the differential biological response of the hit compounds in general provided first indications with respect to the structure–activity relationships and mode of action, respectively.

27 January 2026 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
Muhammad RafehiMuhammad Rafehi
Muhammad Rafehi
FTFranziska Tägl
Franziska Tägl
NANike Sophia Arlt
Nike Sophia Arlt
MNMaria Neif
Maria Neif
KSKatja Stefan
Katja Stefan
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan
Altogether, 60-70% of the ATP-binding cassette (ABC) and solute carrier (SLC) transporters can currently not be targeted by drugs, despite their involvement in human diseases. The design of potential drug candidates relies on hit identification and subsequent optimization with regard to selectivity and specificity. However, these workflows ultimately fail if no hit molecules can be found. We pursued a strategy of rational discovery of hit molecules for 'undruggable' ABC and SLC transporters based on polypharmacology as an alternative approach in the drug development repertoire. The 42 most polypharmacological ABC transporter modulators were profiled against eight specific (NAT, DAT, and SERT) and polyspecific (OCT1-3, MATE1-2K) SLCs. The general hit rate increased expectedly with the degree of polyspecificity, ranging from 0 to 9.52% (NAT, DAT, SERT) to 19.0-52.4% (OCT1-3, MATE1-2K). Striking was the hit rate for potent drugs, which was highest for the specific transporter SERT (75.0%); additionally, pranlukast (PRA) could also be identified as common substrate of NAT, DAT, SERT, and MATE2K. The polypharmacology of drugs correlated with their potency, and a higher degree of polypharmacology against ABCs was reflected in a higher degree of polypharmacology against SLCs. Some compounds mediated between both specific and polyspecific transporters which could be underpinned by the identification of common molecular features ('privileged structures'). The polypharmacology of selected drugs could be transferred to ABCA1 and Oatp1d1, two transporters for which almost no modulators have been reported before. This strategy provided privileged ligands with high potency at high hit rates to challenge transporter undruggability.